

Studying Neurodevelopmental Disorders Through The Lens of *SYNGAP1*


GBM 08/01/2025
Bernadette Basilico

Vietata la diffusione e l'uso delle slide.
Solo scopo didattico.

- Neurodevelopmental disorders (NDDs) are a group of conditions that affects the growth and development of the **brain** or the **central nervous system**.
- The term refer to a disorder of brain function that affects emotion, learning ability, self-control and memory and that unfolds as individual grows.
- The term is sometimes erroneously used as an exclusive synonym for autism spectrum disorders.

The diagnosis of NDDs encompasses **a broad spectrum of disorders** with onset in the developmental period (mostly by the age of 2-5 years). Within the specific **diagnostic category** included in **DSM-5**, the following diagnoses are recognized:

- Intellectual disabilities;
- Communication disorders;
- Autism spectrum disorder (ASD);
- Attention deficit/hyperactivity disorder (ADHD);
- Specific Learning Disorders;
- Neurodevelopmental motor disorders.




Given the large number of conditions included in this diagnostic category, the symptoms with which they may present vary widely depending on the type and severity of the disorder. **The main domains affected** by Neurodevelopmental Disorders are the following:

- **Communication skills**
- **Social skills**
- **Repetitive behaviors**
- Language
- Learning skills
- Memory
- Motor skills
- Intelligence
- Executive functions

Neurodevelopmental milestones

Human brain development is an orchestrated process of time-limited developmental stages.
Any deviations from these developmental trajectories lead to NDDs.



While NDDs-diagnosis typically occurs in childhood, the pathophysiological changes associated may start already during **embryonic development**.



Common Causes




Brain Machinery Changes





Neurodevelopmental Disorders


Common Symptoms



Brain Morphology Changes




Genetic causes: the most common



Mutational load and degree of vulnerability of the disrupted genes influence the phenotypical outcome.


One of the main factors contributing to the development of a Neurodevelopmental Disorder is **genetic predisposition**. In fact, genetics studies conducted in this regard have revealed a significant genetic component underlying these conditions. Many genetic variations and mutations appear to confer an increased **vulnerability toward the development of Neurodevelopmental Disorders**.

These abnormalities may be inherited from parents or may occur spontaneously during fetal development.




Biological subtypes of NDDs


Molecular mechanisms in ASD pathogenesis & drug targets




Genes belonging to this category are transcription factors, chromatin modifiers and genes regulating DNA and histone modifications.



Protein homeostasis is regulated by the interplay of protein synthesis and degradation. Protein abundance is further limited by the availability of amino acids, such as the branched chain amino acids




Cytoskeleton dynamics regulate fundamental brain developmental processes, such as neural migration and differentiation. Several genes converge on the regulation of microtubules and actin organization.



A large number of cell-adhesion and post-synaptic density proteins have been implicated in the aetiology of NDDs. These proteins create an interconnected molecular network stabilizing both inhibitory and excitatory synapses


Synaptic development and plasticity: how neurons communicate

Progressively zoomed-in view from a brain circuit to a neuron to a synapse to an ion channel



Synaptic development and plasticity: how neurons communicate


Progressively zoomed-in view from a brain circuit to a neuron to a synapse to an ion channel



SYNGAP1 – Genetics

SFARI GENE
SCORE
1S

High Confidence, Syndromic
Criteria 1.1, Syndromic



SYNGAP1-Related Disorders is a rare genetic condition caused by a variant on the SYNGAP1 gene (6p.21.32)

Mutations in SYNGAP1:

- Nonsense → haploinsufficiency (protein level reduction)
- Missense → changes in protein functions (no truncation)
- Frameshift
- Splice-site

Phenotype heterogeneity:

- Intellectual disability (100 %)
- Epilepsy (>80 %)
- ASD (50 %)
- Other comorbidities

***SYNGAP1* in intellectual disability: first clinical association in 2009**

The NEW ENGLAND JOURNAL of MEDICINE

2009


BRIEF REPORT

Mutations in *SYNGAP1* in Autosomal Nonsyndromic Mental Retardation

Fadi F. Hamdan, Ph.D., Julie Gauthier, Ph.D., Dan Spiegelman, M.Sc., Anne Noreau, M.Sc., Yan Yang, M.D., Stéphanie Pellerin, R.N., Sylvia Dobrzeniecka, M.Sc., Mélanie Côté, B.Sc., Elizabeth Perreau-Linck, M.Sc., Lionel Carmant, M.D., Guy D'Anjou, M.D., Éric Fombonne, M.D., Anjene M. Addington, Ph.D., Judith L. Rapoport, M.D., Lynn E. Delisi, M.D., Marie-Odile Krebs, M.D., Ph.D., Faycal Mouaffak, M.D., Ridha Joober, M.D., Ph.D., Laurent Mottron, M.D., Ph.D., Pierre Drapeau, Ph.D., Claude Marineau, M.Sc., M.B.A., Ronald G. Lafrenière, Ph.D., Jean Claude Lacaille, Ph.D., Guy A. Rouleau, M.D., Ph.D., and Jacques L. Michaud, M.D., for the Synapse to Disease Group



- 3/94 patients with ID had *de novo* truncating variant
- 0/142 autism
- 0/143 schizophrenia
- 0/190 unaffected
- Several additional studies
 - 18 patients
 - At least 12 w/seizures

SYNGAP1 encephalopathy is associated with a spectrum of comorbid conditions



(Vlaskamp et al 2019)

SYNGAP1 – Genetics



How Many People Have SYNGAP1?

1,530


SYNGAP1 PATIENTS WORLDWIDE

+33 patients found in 4Q24!



cureSYNGAP1.org/Census

Known SYNGAP1 patients worldwide




Source: SYNGAP1 Census 2024

Why genetics is important?

Knowing the genetic diagnosis....


- Improves prognosis counseling
- Facilitates discussion of recurrence risk
- May affect choice of medications
- Provides research opportunities
- Connects families with the same genetic diagnosis

Genetic diagnosis (Epilepsy genes)




GOAL: Identify additional genetic causes of DEE in order to improve diagnosis, genetic counseling for families and, eventually, treatment

Channelopathy Era



Genetic diagnosis (Epilepsy genes)



Next-gen Sequencing

>70 genes


Microdeletions

- 15q13.3 *
- 16p13.11 *
- 15q11.2 *

- CACNA1E*
- GNB1 *
- PPP3CA *
- CUX2 *
- STX1B
- SLC6A1 *
- GABRA1 *
- GABRB3 *
- SIK1
- KCNA2
- ALG13 *
- GRIN2B
- PURA
- KCNB1
- KCNC1
- DNM1 *
- HCN1
- CHD2 *
- SCN8A
- SCN2A
- GRIN2A *
- DEPDC5
- KCNT1
- PRRT2
- TBC1D24
- STXBP1
- PCDH19
- SYNGAP1**

Additional
EE in
diagnosis,
for
usually,

Channelopathy
Era




Why genetics is important?

From diagnosis to treatment




- Studies in cells



- Model organism experiments



- Patient cells: “stem cell” studies



SYNGAP1 discovery in 1998



Neuron



Volume 20, Issue 5, May 1998, Pages 895-904

Article

A Synaptic Ras-GTPase Activating Protein (p135 SynGAP) Inhibited by CaM Kinase II

Hong-Jung Chen¹, Michelle Rojas-Soto¹, Asako Oguni¹, Mary B Kennedy¹*  


Neuron



Volume 20, Issue 4, April 1998, Pages 683-691


Article

SynGAP: a Synaptic RasGAP that Associates with the PSD-95/SAP90 Protein Family


Jee Hae Kim¹, Dezhi Liao¹, Lit-Fui Lau¹, Richard L Huganir¹*  

SYNGAP1 discovery – Huganir lab


Brain-Specific Expression of SynGAP



SynGAP is specifically localized at excitatory synapses




SynGAP is localized to membrane fractions




SYNGAP1 discovery – Kennedy lab



SynGAP is expressed primarily in brain and is localized to synapses containing NMDA receptors.



It constitutes 1%–2% of total protein in isolated PSDs and is rapidly phosphorylated upon activation of CaMKII in the PSD.



SYNGAP1 discovery – Kennedy lab




Hypothesized Effects of Regulation of p135 SynGAP by NMDA-Receptor Activation at Glutamatergic Synapses.

Active p135 SynGAP at postsynaptic densities will keep the steady-state level of active Ras low near the synapse by catalyzing rapid hydrolysis of Ras-GTP to Ras-GDP.

Activation of NMDA receptors produces an influx of Ca²⁺ that activates CaMKII at the postsynaptic density. CaMKII then phosphorylates and inactivates p135 SynGAP, releasing the brake on the accumulation of active Ras-GTP and leading to increased activation of the MAP kinase cascade.

SYNGAP1 – Molecular function

SynGAP as a “molecular hub” for the regulation of synaptic strength at baseline (limiting the number of AMPAR) and following neuronal activity




The postsynaptic density is comprised of membrane receptors and ion channels, scaffold and adaptor proteins, signaling proteins, cell-adhesion molecules and components of the cytoskeleton.

The presynaptic and postsynaptic membranes are connected by cell-adhesion molecules.

SYNGAP1 – Molecular function

“Classic role”: GAP protein that mediates the transition from the active (GTP) to the inactive (GDP) form of small GTPase (e.g. Ras)



As result of the loss of the GTPase activity, small GTP proteins (e.g., Ras, Rap) are inappropriately bound to GTP at too high proportion and for too long


→ SynGAP as an enhancer of GTPase activity

→ Ras signaling overactivation if SynGAP is missing

SYNGAP1 – Molecular function

“Classic role”: GAP protein that mediates the transition from the active (GTP) to the inactive (GDP) form of small GTPase (e.g. Ras)


SynGAP as a “molecular hub” for the regulation of synaptic strength at baseline (limiting the number of AMPAR) and following neuronal activity



- Influence on PSD composition
- Negative regulator of AMPAR trafficking
- Premature maturation of dendritic spines
- Negative regulator of synaptic plasticity
- Excitation/inhibition imbalance
- Cognitive deficits

The SynGAP protein: today

SYNGAP1 Conserved Domains




PH → recruiting proteins to different membranes/compartments; binding of inositol phosphates, and various proteins

C2 → targeting proteins to cell membranes; binding of phospholipids, inositol polyphosphates, and intracellular proteins

RasGAP → catalytic domain; acceleration of the GTPase activity of Ras, thereby "switching" it into an "off" position


Coiled Coil (CC) → protein clustering/oligomerization

SYNGAP1 alternative splicing and resulting isoforms



files


Isoforms expression in mice over time



Fine control of Ras and Rap1 activation during early development – when SYNGAP1 is missing their overactivation could lead to an abnormal development

(Kilinc et al 2018; Araki et al 2020)

Role of SynGAP in determining slot availability for the AMPAR-TARP complex independently of its GAP activity









Model of SynGAP regulation of synaptic plasticity. SynGAP regulates synapses by competing with AMPAR-TARP complexes to form LLPS condensates with PSD95. During LTP induction, phosphorylation of SynGAP promotes the dispersal of SynGAP from the synapse and is replaced with AMPAR-TARP complexes, resulting in the potentiation of synaptic transmission.

SYNGAP1 – Non-canonical role in brain development



New finding : SYNGAP1 is expressed already in radial glia progenitors

Cortical plate disorganization during development affecting cell division mode



SYNGAP1 – Non-canonical role in brain development

Accelerated maturation of cortical projection neurons and iNeurons








(Birtele et al 2023)

(Llamosas et al 2020)

SYNGAP1 – Non-canonical role in brain development


Cortical plate disorganization during development affecting cell division mode




[No Title]

SYNGAP1 research at Sapienza University


Experimental models




Characterization of disease phenotypes



Isogenic mutant single-neural rosettes



Screening of single-neural rosettes.



Development of a drug screening platform

